Icotrokinra Trial for Ulcerative Colitis
Phase 3
882
about 6.3 years
12+
47 sites in AZ, CA, CO +17
About this study
Researchers are testing whether icotrokinra, a medication, can help people with moderately to severely active ulcerative colitis. The trial will last 2295 days and involve approximately 882 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Icotrokinra
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Secondary: DB Induction Study: Percentage of Adult Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), DB Induction Study: Percentage of Adult Participants with Fatigue Response at Week I-12, DB Induction Study: Percentage of Adult Participants with No Abdominal Pain at Week I-12, DB Maintenance Study: Percentage of Adult Participants with AEs and SAEs, DB Maintenance Study: Percentage of Adult Participants with Disease Clearance at Week M-40, DB Maintenance Study: Percentage of Adult Participants with Fatigue Response at Week M-40, DB Maintenance Study: Percentage of Adult Participants with No Abdominal Pain at Week M-40, OL Induction Phase: Percentage of Adolescent Participants with AEs and SAEs
Gastroenterology